Global Immunoassay Market Overview:
Immunoassay is a highly selective bioanalytical method that measures the presence or concentration of analytes ranging from small molecules to macromolecules in a solution through the use of an antibody or an antigen as a biorecognition agent. It helps to detect the antigens of viruses, bacteria, parasites, hormones and markers that are specific to a certain disease. It is useful in various bioanalytical settings such as clinical diagnostics, biopharmaceutical analysis, environmental monitoring, security and food testing. A substantial rise in the cases of infectious and chronic disease and the rise in the use of immunoassays in oncology are likely as the main factors that are projected to support the development of the market in the coming years. Moreover, the high development in biopharmaceutical and biotechnology industries is another factor that is predicted to create potential growth opportunities over the coming years. As per latest study released by AMA Research, the Global Immunoassay market is expected to see growth rate of 6.5%
|Value (USD Million)
|Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility
- Growth in the Biotechnology and Biopharmaceutical Industries
- Rising Incidence Rate of Chronic and Infectious Diseases
- Increasing Adoption of Immunoassay Based Testing
- Stringent Regulatory Requirements for Instrument Approval
- High Prices Of the Immunoassay Systems
- Growth Opportunities in the Emerging Countries
- Rising Geriatric Population
- Technical Difficulties during Testing
Some of the key players profiled in the report are Bio-Rad Laboratories, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Siemens Healthineers (Germany), Becton, Dickinson and Company (United States), Danaher Corporation (United States), bioMérieux Inc. (France), Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland), Sysmex Corporation (Japan) and Abcam plc. (United Kingdom). Analyst at AMA Research see United States Players to retain maximum share of Global Immunoassay market by 2027. Considering Market by , the sub-segment i.e. will boost the Immunoassay market. Considering Market by Platform, the sub-segment i.e. Chemiluminescence Immunoassays will boost the Immunoassay market. Considering Market by Technology, the sub-segment i.e. Enzyme-Linked Immunosorbent Assays will boost the Immunoassay market.
Latest Market Insights:On 15th December 2017, Siemens Healthineers acquired Luxembourg-based Fast Track Diagnostics (FTD), a global supplier of diagnostics tests. By introducing FTD products to its molecular diagnostics portfolio, Siemens Healthineers is further investing in precision medicine and better patient experience through solutions that eliminate the need for repeat diagnostic testing, reducing time and improving patient outcomes.
On 10th April 2019, Thermo Fisher Scientific, the world leader in serving science, launched Immunoassay for Kratom Alkaloid Mitragynine Screening. It’s the newest drug to abuse test supporting calibrators and controls. and In 2018, the World Hepatitis Alliance launched the “Find the Missing Millions” campaign to raise awareness regarding hepatitis and remove barriers in clinical diagnostic settings.
What Can be Explored with the Immunoassay Market Study Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Immunoassay Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Immunoassay
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:The top-down and bottom-up approaches are used to estimate and validate the size of the Global Immunoassay market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Immunoassay market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceutical and Biotechnology Companies, Hospitals, Clinical Laboratories, Blood Banks, Research and Academic Laboratories and End-user.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.